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Background: Patients with end-stage renal disease (ESRD) are at a higher risk for chronic hepatitis, liver cirrhosis
(LC) and mortality than the general population. Optimal modalities of renal replacement therapy for ESRD patients
with concomitant end-stage liver disease remain controversial. We investigated the long-term outcome for chronic
liver disease among dialysis patients in an endemic area.
Methods: Using Taiwan’s National Health Insurance claim data (NHRI-NHIRD-99182), We performed a longitudinal
cohort study to investigate the impact of comorbidities on mortality in dialysis patients. We followed up 11293
incident hemodialysis (HD) and 761 peritoneal dialysis (PD) patients from the start of dialysis until the date of death
or the end of database period (December 31, 2008). A Cox proportional hazards model was used to identify the risk
factors for all-cause mortality.
Results: Patients receiving PD tended to be younger and less likely to have comorbidities than those receiving HD.
At the beginning of dialysis, a high prevalence rate (6.16 %) of LC was found. Other than well-known risk factors, LC
(hazard ratio [HR] 1.473, 95 % CI: 1.329-1.634) and dementia (HR 1.376, 95 % CI: 1.083-1.750) were also independent
predictors of mortality. Hypertension and mortality were inversely associated. Dialysis modality and three individual
comorbidities (diabetes mellitus, chronic lung disease, and dementia) interacted significantly on mortality risk.
Conclusions: LC is an important predictor of mortality; however, the effect on mortality was not different between
HD and PD patients.
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The global prevalence and incidence of end-stage renal dis-
ease (ESRD) has been increasing annually [1,2]. The results
of studies [3-8] on outcomes among dialysis patients appear
to vary by country, follow-up period, age, baseline comor-
bidities, dialysis types and choice of study design.* Correspondence: rockiekan@ntu.edu.tw
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reproduction in any medium, provided the orThe survival of hemodialysis (HD) and peritoneal dialy-
sis (PD) seem inconclusive [8]. Age, type of dialysis [7],
diabetes mellitus (DM), and other comorbidities need to
be considered when estimating mortality among dialysis
patients [3-5]. Elderly patients on PD are reported to have
a poor prognosis [4-6], patients with diabetes receiving
PD have been found to have a higher mortality than those
receiving HD [3,4,6]. While Jaar BG et al. reported that
ESRD patients who had higher propensity for initially re-
ceiving PD, survival did not differ by dialysis type [7].
Patients with ESRD are at a higher risk for chronic hepa-
titis, and thus are more likely to have higher rates oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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higher mortality than the general population [9-16]. Tai-
wan is an endemic area for HCV. There, PD patients have
a HCV prevalence rate of 10 % – 15 % [17,18], HD
patients 15 % – 20 %, and the general population 5 % –
10 % [12,13]. Around ten percent of incident dialysis
patients have been found to be positive for anti-HCV anti-
body [14], and 5.8 % of incident HD patients have been
found to have LC [15] when beginning renal replacement
therapy in Taiwan. Optimal modalities of renal replace-
ment therapy for these patients also remain controversial
[19-21]. Potential disadvantages of HD therapy are un-
stable hemodynamics and the risk of bleeding [19,22].
While PD therapy offers a more stable hemodynamic pro-
file, it may increase the possibility of early catheter leak,
peritonitis, and ongoing protein loss. HD has been
reported to not prolong survival in LC patients with acute
kidney injury (AKI), but not been carefully examined in
those with maintained HD. While PD is also reported to
be unhelpful in LC with AKI, but it has been found to
produce viable results in some LC patients with ESRD
[20].
We hypothesize that each comorbidity has a different
impact on the long-term survival and mortality rates be-
tween HD and PD patients. The Asia-Pacific area is highly
endemic for chronic liver disease [10,11,23]. However,
published studies on this subject for Asian populations are
scarce, especially epidemiological data for a national co-
hort of incident dialysis patients [6]. Using data from the
Taiwan National Health Insurance (NHI) database form
1999 to 2008, we investigated the factors that may have an
impact on mortality in dialysis patients.
Methods
Data sources
The National Health Insurance (NHI) program has pro-
vided compulsory universal health insurance in Taiwan
since 1995. With the exception of prison inmates, all
citizens are enrolled in the program. All medical institu-
tions contracted with the NHI program must submit
standard computerized claim documents for medical
expenses. Patients with ESRD are eligible for any type of
renal replacement therapy for free of charge; the
expenses of chronic dialysis patients are covered by
NHI.
Data for the study was obtained from the National
Health Insurance Research Database (NHIRD) [Bureau of
National Health Insurance. Available at: www.doh.gov.tw/
statistic/index.htm [In Chinese] (accessed November 25,
2011); http://www.doh.gov.tw/EN2006/index_EN.aspx [In
English], which was released for research purposed by the
Taiwan National Health Research Institute (NHRI). This
database covers nearly all (99 %) inpatient and outpatient
medical benefit claims for Taiwan’s 23 million residents,making it one of the largest and most comprehensive
databases in the world, and has been used extensively in
various studies [24]. Patient identification numbers, gen-
der, birthdays, dates of admission and discharge, medical
institutions providing the services, the ICD-9-CM (Inter-
national Classification of Diseases, 9th Revision, Clinical
Modification) diagnostic (up to five) and procedure codes
(up to five), and outcomes are encrypted. As the dataset
was released with deidentified secondary data for public
research purposes, the study was exempt from full review
by the Institutional Review Board of Chi-Mei medical cen-
ter and the Bureau of National Health Insurance (NHRI-
NHIRD-99182). We used the NHIRD for all ambulatory
care claims and inpatient claims from 1998 to 2008 for
this study. All datasets can be interlinked through the
individual’s unique personal identification number.
Patient selection and definition
In this longitudinal cohort study, we selected all adult
ESRD patients (≥18 years old) on maintenance dialysis
who began renal replacement therapy between January 1st,
1999, and December 31st, 2000 (n= 12902). ESRD patients
on maintenance dialysis were defined as receiving dialysis
for more than 90 days [3,15], our indicator of a need for
long-term dialysis. We excluded those who had under-
gone renal transplantation before beginning dialysis
(n= 81). Patients were followed from the first reported
date of dialysis to the date of death or December 31st,
2008, the end of the database period. We also excluded
patients who received renal transplantation (n= 693) dur-
ing the follow-up period or underwent multiple switches
between HD and PD (n= 83). The determination of mo-
dality switches after the initial modality choice followed
the “60-day rule” used by the USRDS (i.e., any change in
modality lasting less than 60 days is not recorded as a
“switch” in the database) [25]. In total, we analyzed data
collected from 11293 incident HD and 761 incident PD
patients (Figure 1).
Ascertaining the demographic and comorbid variables
We linked to the diagnostic codes through the inpatient
and outpatient claims databases of the NHI. Our data col-
lection included not only patients` survival status, but also
their date of death, demographics, and baseline comorbid-
ities. Baseline comorbidities, including diabetes (DM),
hypertension (HTN), congestive heart failure (CHF), coron-
ary artery disease (CAD), cerebrovascular accident (CVA),
peripheral arterial disease (PAD), chronic lung disease, liver
cirrhosis (LC), cancer, dementia, and hemiplegia or paraple-
gia, are important factors affecting mortality and were
assessed at the start of dialysis. These characteristics were
consistent with those in previous studies [3,26] and demon-
strate the need to adjust when comparing mortality rates
among dialysis patients. The ICD-9-CM codes used to
Figure 1 Flowchart showing incident dialysis population for
evaluating long-term outcomes.
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bidities were identified according to one of the definitions
below: (1) Diagnostic codes in outpatient visits if the patient
had an initial diagnosis at any time the year leading up to
beginning of dialysis and then experienced one or more
additional diagnoses within the subsequent 12 months. The
first and last outpatient visit within 1 year must had to be
>30 days apart to avoid accidental inclusion of miscoded
patients. [27,28] (2) Diagnostic codes in hospitalization
databases at least one time within the year leading up to
start of dialysis. The method of identifying these comorbid-
ities have been used extensively in various studies of Taiwan
National Health Research Institute and many articles have
been published [Bureau of National Health Insurance.Table 1 ICD −9-CM codes used to identify clinical
conditions
Conditions ICD-9-CM
Diabetes Mellitus 250.**, 357.2, 362.0*, 366.41
Hypertension 362.11, 401.*-405.*, 437.2
Congestive Heart Failure 398.91, 422, 425, 428, 402.*1, 404.*1, 404.*3
Coronary Artery Disease 410.**- 414.**
Cerebrovascular Accident/TIA 430-438.**
Peripheral Arterial Disease 440-440
Chronic Lung Disease 490-496*, 500-505*, 506.4*
Liver Cirrhosis 571.5, 571.6
Cancer 140-208; 230–231; 233-234
Dementia 290-290.9*
Hemiplegia or Paraplegia 344.1*, 342–342.9*
ICD-9-CM, International Classification of Diseases, Ninth Revision, Clinical
Modification; TIA, Transient ischemic attack. * can be any number or missing.Available at: www.doh.gov.tw/statistic/index.htm [In Chin-
ese] (accessed November 25, 2011); http://www.doh.gov.tw/
EN2006/index_EN.aspx [In English].
Statistical analyses
Parametric Pearson’s chi square test is utilized to compare
each variable in HD and PD patients. Non-parametric
tests were used for other analyses. The significance was
set at P< 0.05.
Overall patient survival was described using the Kaplan-
Meier method based on dialysis modality. Intent-to-treat
analysis was analyzed using Cox proportional hazards
model to identify the risk factors for all-cause mortality.
Hazard ratios (HRs) and 95 % confidence intervals (CIs)
were derived from Cox proportional hazards models. Cox
models met the assumption of proportionality of risks. To
adjust for potential confounding in the relationship be-
tween comorbidities and the risk of mortality, multivariate
analyses were used to model to all-cause mortality. Fur-
ther interactions were tested. The complete model, which
included all the covariates, was used for cox regression
analysis. Then, each interaction term was separately
included once at a time. All statistical operations were
performed using the Statistical Package for Social Sciences
for Windows 17.0 (SPSS Inc; Chicago, IL, USA).
Results
Demographics and clinical characteristics
Initially, 11293 patients selected HD and 761 patients
selected PD (Table 2). PD patients tended to be younger
and to less likely have comorbidities than those receiving
HD. Patients receiving PD were predominantly younger
than those receiving HD (53.95± 15.09 years vs.
59.87 ± 13.45 years). During the follow-up period, 11216
patients (93.0 %) received pure HD treatment, 513
patients (4.3 %) received pure PD treatment, 77 patients
(0.6 %) switched from HD to PD treatment, and 248
patients (2.1 %) switched from PD to HD. Many more HD
patients than PD patients had DM and cardiovascular dis-
eases, including CHF, CAD, and CVA. There were no sig-
nificant differences between these two dialysis with regard
to HTN, PAD, LC, cancer, dementia, and hemiplegia or
paraplegia. Around six percent (6.2 %) of HD patients and
5.3 % of PD patients had LC.
Cumulative survival rate
During the follow-up period, 5374 patients died. The
Kaplan-Meier survival curves for initial HD and initial PD
patients can be viewed in Figure 2. For the PD group,
mean follow-up time alive on dialysis was 91.39 months
(95 % CI: 88.43-94.34), and for the HD group 83.20 months
(95 % CI: 82.43-83.98). The cumulative survival rate of PD
patients was 97.1 % at one year, 73.5 % at five years, and
57.8 % at nine years. The cumulative survival rate of HD
Table 2 Patient characteristics and association with
dialysis modality
PD (n = 761) HD (n= 11293) P-value
n (%) n (%)
Gender 0.004
Female 445 (58.50) 5997 (53.10)
Male 316 (41.50) 5296 (46.90)
Age (years) <0.001
18-44 217 (28.50) 1584 (14.00)
45-64 347 (45.60) 5067 (44.90)
≥65 197 (25.90) 4642 (41.10)
Cause of ESRD <0.001
Non-Diabetes Mellitus 478 (62.80) 5471 (48.40)
Diabetes Mellitus 283 (37.20) 5822 (51.60)
Baseline Comorbidity
Hypertension 0.548
No 187 (24.60) 2667 (23.60)
Yes 574 (75.40) 8626 (76.40)
Congestive Heart Failure <0.001
No 567 (86.30) 9172 (81.20)
Yes 104 (13.70) 2121 (18.80)
Coronary Artery Disease 0.01
No 614 (80.70) 8655 (76.60)
Yes 147 (19.30) 2638 (23.40)
Cerebrovascular Disease 0.002
No 698 (91.70) 9224 (87.90)
Yes 63 (8.30) 1369 (12.10)
Peripheral Arterial Disease 0.152
No 740 (97.20) 10867 (96.20)
Yes 21 (2.80) 426 (3.80)
Chronic Lung Disease <0.001
No 716 (94.10) 10094 (89.40)
Yes 45 (5.90) 1199 (10.60)
Liver Cirrhosis 0.282
No 721 (94.70) 10590 (93.80)
Yes 40 (5.30) 703 (6.20)
Cancer 0.46
No 741 (97.40) 10831 (95.90)
Yes 20 (2.60) 462 (4.10)
Dementia 0.072
No 757 (99.50) 11150 (98.70)
Yes 5 (0.50) 143 (1.30)
Hemiplegia or Paraplegia 0.785
No 750 (98.60) 11143 (98.70)
Yes 11 (1.40) 150 (1.30)
PD: Peritoneal dialysis; HD: Hemodialysis; ESRD: End-stage renal disease.
Figure 2 Crude overall survival curves for incident end-stage
renal disease patients stratified by HD and PD at the start of
dialysis.
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44.1 % at nine years. The differences in survival between
PD and HD patients were significant (log-rank: P <0.001).
Risk factors for all-cause mortality in all dialysis (HD and
PD) patients
Based on a proportional hazards analysis performed to esti-
mate the risk factors for all-cause mortality in dialysis
patients, adjusted survival rates of HD versus PD patients
were not significantly different (hazard ratio [HR] 0.882,
95 % CI: 0.776-1.001) (Table 3). There are several factors in-
dependently associated with mortality. Male patients had a
higher mortality rate than female patients. Patients with
DM, CHF, CAD, CVA, PAD, chronic lung disease, LC, can-
cer, dementia, and hemiplegia or paraplegia had a signifi-
cantly higher mortality. However, patients with baseline
HTN had lower mortality than those without HTN (HR
0.905, 95 % CI: 0.845-0.970). Further interactions between
HTN and these comorbidities were tested. There was only
one significant interaction: HTN×LC (P <0.001). After
stratification, the effect of baseline HTN on lower mortality
was much more prominent in LC patients (HR 0.726, 95 %
CI: 0.573-0.920) than in non-LC patients (HR 0.924, 95 %
CI: 0.860-0.933).
Using all-cause mortality as the outcome, only
three significant factors that interacted with dialysis
mortality: DM, chronic lung disease, and dementia
(Table 4).
Risk factors for all-cause mortality among HD patients
We further stratified patients by dialysis modality.
After multivariate analyses, we found an association
between male gender and older age and higher mor-
tality rates (Table 5). Baseline HTN was associated
with lower mortality in HD patients (HR 0.904, 95 %
Table 3 Multivariable-adjusted model for all-cause





Covariate HR (95% CI) HR (95% CI)
Initial dialysis modality
(HD vs. PD)
1.419 (1.251-1.609)* 0.882 (0.776-1.001)
Gender (Male vs. Female) 1.238 (1.174-1.306)* 1.192 (1.129-1.258)*
Age at initiation of
Dialysis (years)
18-44 Referent Referent
45-64 2.710 (2.434-3.016)* 2.165 (1.942-2.415)*
≥65 5.709 (5.132-6.351)* 4.441 (3.979-4.956)*
Diabetes Mellitus (yes vs. no) 2.244 (2.124-2.371)* 1.841 (1.736-1.951)*
Hypertension (yes vs. no) 1.312 (1.228-1.401)* 0.905 (0.845-0.970)*
Congestive Heart Failure
(yes vs. no)
1.969 (1.846-2.099)* 1.445 (1.348-1.549)*
Coronary Artery Disease
(yes vs. no)
1.778 (1.675-1.888)* 1.127 (1.056-1.202)*
Cerebrovascular Disease
(yes vs. no)
1.906 (1.766-2.057)* 1.303 (1.201-1.413)*
Peripheral Arterial Disease
(yes vs. no)
1.829 (1.604-2.086)* 1.310 (1.147-1.496)*
Chronic Lung Disease
(yes vs. no)
1.709 (1.575-1.855)* 1.222 (1.124-1.329)*
Liver Cirrhosis (yes vs. no) 1.612 (1.455-1.787)* 1.473 (1.329-1.634)*
Cancer (yes vs. no) 1.593 (1.405-1.807)* 1.368 (1.205-1.553)*
Dementia (yes vs. no) 1.910 (1.506-2.422)* 1.376 (1.083-1.750)*
Hemiplegia or Paraplegia
(yes vs. no)
2.094 (1.700-2.580)* 1.445 (1.162-1.796)*
HR: Hazard ratio; CI: Confidence interval; *P <0.05.






Covariate HR (95% CI) HR (95% CI)
Gender (Male vs. Female) 1.224 (1.158-1.293)* 1.191 (1.127-1.258)*
Age at initiation of dialysis
(years)
18-44 Referent Referent
45-64 2.682 (2.395-3.003)* 2.148 (1.915-2.409)*
≥65 5.583 (4.990-6.246)* 4.378 (3.903-4.910)*
Diabetes Mellitus (yes vs. no) 2.183 (2.063-2.310)* 1.821 (1.715-1.933)*
Hypertension (yes vs. no) 1.313 (1.228-1.405)* 0.904 (0.843-0.971)*
Congestive Heart Failure
(yes vs. no)
1.919 (1.797-2.050)* 1.436 (1.338-1.541)*
Coronary Artery Disease
(yes vs. no)
1.742 (1.639-1.853)* 1.125 (1.052-1.202)*
Cerebrovascular Disease
(yes vs. no)
1.853 (1.715-2.003)* 1.298 (1.192-1.410)*
Peripheral Arterial Disease
(yes vs. no)
1.815 (1.587-2.075)* 1.310 (1.144-1.499)*
Chronic Lung Disease
(yes vs. no)
1.666 (1.533-1.810)* 1.209 (1.111-1.317)*
Liver Cirrhosis (yes vs. no) 1.612 (1.451-1.790)* 1.478 (1.330-1.643)*
Cancer (yes vs. no) 1.565 91.375-1.780)* 1.361 (1.195-1.549)*




HR: Hazard ratio; CI: Confidence interval; *P <0.05.
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were independent risk factors for higher mortality.
Risk factors for all-cause mortality among PD patients
Multivariate analyses revealed no significant differences in
the risk factors for all-cause mortality between male and
female PD patients (Table 6), though risk of mortality
increased with age, especially in PD patients. Only old age,
DM, CHF, and chronic lung disease were found to be in-
dependent risk factors for mortality in PD patients.Table 4 Interaction between dialysis modality and each
comorbidity
Interaction between dialysis modality and each
comorbidity
P-value
Diabetes Mellitus ×Dialysis modality 0.040
Chronic Lung Disease ×Dialysis modality 0.025
Dementia ×Dialysis modality 0.042
The complete model included all the covariates listed in Table 3 was used for
cox regression analysis. Then, each interaction term was included separately
once at a time.Discussion
This study used Taiwan NHI database, representing na-
tionwide and representative population, to investigate
long-term survival and mortality risk among dialysis
patients. We found a high prevalence of LC among inci-
dent dialysis patients in our registry. The effects of some
baseline comorbidities—DM, chronic lung disease, and
dementia—on long-term mortality were not identical be-
tween HD and PD. Importantly, LC and dementia, in
addition to the well-known risk factors, were predictors
for mortality. In contrast, we found an inverse associ-
ation between HTN and death.
Patients receiving PD had a better crude survival rate
than those receiving HD. Those who selected PD were
generally less likely to have comorbidities (Table 2). The
HD group seemed to have a disproportionately higher
number of the elderly patients. After adjustment, there
was no statistical difference in terms of survival between
the HD and PD groups. However, old age appeared to be
the most important factor influencing survival in both
groups. Patients aged ≥65 had a more than a 4-fold
increase in mortality over those aged 18–44 (Table 3).
We hypothesized that age might have confounded our






Covariate HR (95% CI) HR (95% CI)
Gender (Male vs. Female) 1.419 (1.110-1.814)* 1.202 (0.929-1.554)
Age at initiation of dialysis
18-44 Referent Referent
45-64 2.742 (1.939-3.876)* 2.113 (1.480-3.017)*
≥65 7.810 (5.363-11.373)* 5.224 (3.503-7.851)*
Diabetes Mellitus (yes vs. no) 3.198 (2.494-4.102)* 2.226 (1.700-2.914)*
Hypertension (yes vs. no) 1.216 (0.915-1.617) 0.944 (0.702-1.269)
Congestive Heart Failure
(yes vs. no)
3.042 (2.201-4.204)* 1.746 (1.216-2.506)*
Coronary Artery Disease
(yes vs. no)
2.413 (1.812-3.211)* 1.143 (0.825-1.583)
Cerebrovascular Disease
(yes vs. no)
3.297 (2.239-4.856)* 1.481 (0.939-2.337)
Peripheral Arterial Disease
(yes vs. no)
1.959 (1.007-3.814)* 1.320 (0.665-2.618)
Chronic Lung Disease
(yes vs. no)
2.821 (1.782-4.467)* 1.819 (1.090-3.038)*
Liver Cirrhosis (yes vs. no) 1.527 (0.920-2.533) 1.424 (0.848-2.391)
Cancer (yes vs. no) 2.123 (1.159-3.889)* 1.290 (0.685-2.429)
Dementia (yes vs. no) 8.764 (2.764-27.790)* 3.473 (0.977-12.347)
Hemiplegia or Paraplegia
(yes vs. no)
2.324 (0.958-5.638) 1.223 (0.462-3.240)
HR: Hazard ratio; CI: Confidence interval; *P <0.05.
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ate analysis to estimate the risk factors for mortality, we
found the two dialysis groups to have significantly differ-
ent survival rates (HR 1.419, 95 % CI: 1.251-1.609)
(Table 3). If we further adjust for mode of dialysis and
age, the survival rate for HR went from 1.419 (95 % CI:
1.251-1.609) to 1.024 (95 % CI: 0.902-1.162), indicating
that age confounded the finding of poor prognosis sur-
vival in the HD population. As seen in Figure 2, those
receiving PD had varying rates of survival, while
those receiving HD had almost linear pattern of sur-
vival. Several studies have reported that PD patients
have better survival than HD patients during the first
2 years of dialysis [8,29,30]. The initial benefit of PD
to patients may be found in fewer comorbidities, the
removal of unidentified solutes by PD, or better pres-
ervation of residual renal function during this time
period [29,30]. Having HD catheter may also be a
reason for better initial survival of PD patients [31].
The concept of PD first and HD second implies that
these two modalities of dialysis are complementary,
and not in competition [8].After the interaction test, three baseline comorbidities
(DM, chronic lung disease, and dementia) interacted sig-
nificantly with dialysis modality, indicating that these three
factors had different impact on mortality between HD and
PD patients. Similar to previous findings [3,4,11], the dia-
betes patients in our study had a higher mortality rate in
the PD group (HR=2.210) than those in the HD group
(HR=1.821). One study has reported that a diagnosis of
dementia before the initiation of dialysis predicted subse-
quent death [32]. Likewise, we found our PD patients with
dementia to be at greater disadvantage (HR=3.473), the
possible causes being peritonitis and their inability to do
self-dialysis. Cavanaugh et al. [33] reported that patients
who had chronic obstructive pulmonary disease were at
greater risk of death in dialysis. Similarly, our multivariate
analysis revealed that chronic lung disease to be an im-
portant predictor of mortality, even in patients on PD. We
found a 21 % increase in the risk of death in patients on
HD and an 82 % increase in those on PD. Therefore, it is
important to individualize choice of dialysis modality. To
do this, clinicians will need to consider the important fac-
tors that have different impact on survival between HD
and PD -- DM, chronic lung disease, and dementia. In our
study, ESRD patients with these three comorbidities at
baseline had a higher mortality on those receiving PD than
those on receiving HD.
After stratification, baseline comorbidities with cardio-
vascular diseases (CAD, CVA, and PAD), LC, and cancer
were risk factors for death in HD patients, but not in PD
patients. However, the HR estimates were remarkably
similar, and interactions between treatment modality
and these comorbidities were not significant. After the
interaction test, there was a lack of significance because
we believe PD group was too small to provide statistical
power in our analysis.
Chronic liver disease and ESRD are serious common
medical problems worldwide. Compared with the general
population, ESRD patients are at increased risk of hepatitis
B and C infection [10,11]. Period-prevalent data recorded
in the national or regional dialysis registries of the ten Asia-
Pacific countries/areas reveal the prevalence of HCV infec-
tion is considerably higher in dialysis patients than those in
the corresponding general populations in many Asian
countries (range 1.0–2.9 %) [23], and is likely to contribute
to LC and death [16]. Around six percent (6.2 %) of our
HD patients and 5.3 % of our PD patients had LC at the ini-
tiation of dialysis in Taiwan between 1999 and 2000, a
prevalence which is much higher than that reported for
western countries [30]. The treatment of ESRD patients
with LC is complex and difficult, mainly due to deceased ef-
fective arterial volume and hemodynamic instability. The
best dialysis modality for these patients is still controversial.
Unstable hemodynamics and the risk of bleeding render
HD problematic. Although PD has some disadvantages
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protein loss), some reports still suggest that ESRD patients
with LC can be successfully managed on PD [19,22], though
we found no significant difference between HD and PD on
all-cause mortality. De Vecchi et al. [34] reported dialysis
patients with LC and those without liver disease had similar
survival rates. In contrast, we found a 47 % higher risk of
death in dialysis patients with LC than those without LC
(HR 1.473, 95 % CI: 1.329-1.634).
The current study found that baseline HTN tended to be
associated with decreased mortality among dialysis patients.
The influence of blood pressure on the prognosis of dialysis
patients is controversial [35-38]. While Salem et al. [37]
suggested that antihypertensive treatment had a favorable
effect on survival in dialysis patients, one recent study [36]
reported an association between higher blood pressure and
decreased mortality in dialysis patients without cardiovas-
cular comorbidity. The results of our interaction test, sup-
ports the inverse association between HTN and mortality
in non-DM patients (HR 0.810, 95 % CI: 0.739-0.889), but
not in DM patients (HR 0.992, 95 % CI: 0.891-1.104). How-
ever, we cannot conclude that HTN per se or taking anti-
hypertensive drugs produced the effect. Additional trials are
required to investigate this issue. Some studies [38] found
that arterial pressure can be a marker of organ failure. Our
analysis showed that the effect of HTN on decreased mor-
tality was much more prominent in LC patients than in
non-LC patients. This may indicate that a higher arterial
pressure predicts a lower rate of organ failure in LC
patients on maintenance dialysis.
This study has several limitations. One limitation was
that the comorbidity results relied on the claims data and
ICD-9-CM diagnosis codes, which could potentially lead
to disease misclassification. If these comorbidities were
defined by ICD-9 codes only, then patients might have LC
in several special situations, e.g., subclinically prior to dia-
lysis, not coded for during outpatient ambulatory visit or
hospitalization. Another limitation was that LC may or
may not be related to viral hepatitis. However, we can’t
have access to information about Hepatitis B or C positiv-
ity from this database. Still another limitation is one
related to our use of billing data. This limited our access
to of the body mass index, severity of comorbidities, and
actual blood pressure values of the study population. Our
study also lacked specific data on dialysis adequacy, type
of vascular access used for HD patients, laboratory data,
and medical prescriptions, which may affect survival par-
ticularly in patients with LC. Another might be our defin-
ing ESRD based on maintenance dialysis for more than
90 days. This lateness cause some early mortality related
to LC to be missed. Finally, there may be some residual
confounding as with all observational studies, and thus we
can only show association, not causality, between these
risk factors and mortality.Conclusions
In conclusion, this nationally representative study of in-
cident dialysis patients found three baseline comorbid-
ities, DM, chronic lung disease, and dementia, to have
different effects on long-term outcomes in HD and PD
patients. Taiwan is an endemic area for chronic hepatitis.
This study showed that LC was an important predictor
of mortality; however, the effect on mortality was not
different between HD and PD patients. We found an in-
verse association between baseline HTN and subsequent
mortality. In dialysis patients, a higher arterial pressure
may indicate a lower rate of organ failure in patients
with LC. Identifying high-risk patients at the start of dia-
lysis might lead to more intensified treatment for these
patients and thereby achieve better outcomes.
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